NCT02664571

Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis

Evaluation of Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Centre Hospitalier Universitaire de Nīmes · Academic / Other
• Sex: All
• Age: 60 Years
• Healthy volunteers: Accepted

Summary

The main objective of this study is to compare the distribution of Florbetaben (NEURACEQ: FBB) in the brain in amyloid cerebral angiopathy (ACA) manifested by isolated hemosiderosis in non-demented patients with that observed in healthy subjects, patients with ACA and with lobar hematoma(s) and patients with Alzheimer's dementia without MRI signs in favor of ACA.

Detailed description

The secondary objectives of this study are to compare among groups: A. The associated micro-bleeds. B. Associated leukoencephalopathy. C. Contrast observed in lobar Virchow-Robin perivascular spaces. D. Apolipoprotein E genotypes.

Conditions

• Amyloid Cerebral Angiopathy
• Alzheimer Disease

Interventions

Type	Name	Description
DEVICE	Pet scan with FBB	Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care. Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself.
DEVICE	MRI scan	Subjects will have an MRI scan at inclusion.
BIOLOGICAL	APO E genotyping	Subjects will have APO (apolipoprotein) E genotyping if not already known.

Timeline

• Start date: 2020-07-01
• Primary completion: 2021-07-01
• Completion: 2021-07-01
• First posted: 2016-01-27
• Last updated: 2021-01-25

Locations

2 sites across 1 country: France